To search for targeted synergies, we combined the growth factor signaling inhibitor TAK-165 with an inhibitor of proliferation (trametinib) or a cell cycle inhibitor (MLN-8054) in proliferation assays with the KRAS-mutant A427 lung cancer cell line (Fig 11, S7 and S8 Figs). The gene discussed is KRAS; the disease is lung carcinoma.